Updated May 22, 2026
A client calls. They need design controls documentation, risk management files, V&V protocols, and a regulatory submission strategy — all for a connected diagnostic device with embedded ML. Your team can do it. You’ve done it a hundred times. But the client also wants to understand how AI will change their post-market surveillance, how their design history file can become a living intelligence asset, and whether you can help them operationalize governed AI across their device ecosystem.
You pause. Because that second set of questions isn’t what your firm was built to answer. And you know that three other consultancies got the same call this week.
This is the inflection point, and it’s worth naming directly. The work MedTech consultancies have always done — design controls, V&V, regulatory submissions, risk management — is being subsumed into a larger demand for connected, governed, lifecycle-spanning intelligence. The firms that recognize this and architect the shift will define the next era of MedTech consulting. The firms that bolt on ChatGPT and call it innovation will not.
The Model That Built MedTech Consulting Is Under Structural Pressure
MedTech consultancies built their businesses on deep expertise delivered through people. Documentation specialists, regulatory strategists, V&V engineers, quality system architects. The delivery model is fundamentally labor-intensive: assemble evidence, write protocols, build design history files, prepare submissions, manage post-market compliance. This model works. It’s proven. And it’s increasingly vulnerable.
Pressure is coming from above. Device OEMs and startups are asking why they’re paying for human labor when the underlying work — evidence assembly, traceability across the design history file, compliance orchestration from concept through post-market — could be governed by intelligent systems. They’re not wrong to ask. The question deserves a real answer, not a defensive one.
Pressure is coming from below as well. AI-native entrants are building compliance and regulatory tools that don’t have the domain depth of established consultancies but have the speed advantage of being built on modern stacks from day one. Clients notice. And while these tools rarely survive a serious audit, their existence shifts what “fast enough” looks like in the buyer’s mind.
The squeeze is most acute in the dangerous middle. Mid-sized consultancies in the $20M-$100M revenue band are caught between large system integrators adding MedTech practices to expand their footprint and AI-native startups automating the documentation layer. The traditional response — “our people are better” — is true but insufficient. Better people producing the same artifacts the same way no longer constitutes a defensible moat.
Then there is the ChatGPT misunderstanding. Many firms believe that giving every consultant access to a general-purpose AI tool solves the problem. It doesn’t. Generic AI tools don’t understand design controls. They can’t reason across ISO 13485 clauses, 21 CFR Part 820, IEC 62304, and EU MDR simultaneously. They can’t produce audit-ready evidence packages. They create the illusion of productivity while leaving the regulated last mile — the part the FDA actually cares about — entirely unaddressed. The same emotional fatigue we’ve documented in AI Frustration in Life Sciences & MedTech is the predictable result.
The shift isn’t just about productivity. It’s structural. Clients want outcomes, not bodies. And the economics of expertise-delivered-through-labor are being challenged by a fundamentally different model: expertise-delivered-through-governed-intelligence.
What Clients Are Actually Asking For (Even If They Don’t Have the Words Yet)
When clients say they want “more AI in the engagement,” what they usually mean is something much more specific. They want connected traceability — not just a design history file, but a living fabric that connects user needs to design inputs to design outputs to verification to validation to regulatory submission to post-market surveillance. One governed thread, not twelve disconnected documents living in shared drives and PLM checkouts.
They want risk intelligence, not risk documents. Risk management that updates dynamically as the design evolves, that flags new failure modes when a design change triggers a cascade, that connects risk controls to verification evidence automatically rather than relying on a quality engineer to manually re-thread the trace matrix after every CR.
They want regulatory context awareness. A system that understands the intersection of ISO 13485, IEC 62304, IEC 60601, FDA guidance documents, and EU MDR/IVDR — and that can reason about which requirements apply to a specific device and how they interact. Not a chatbot that quotes regulations. A system that knows which clauses actually bind for this device, in this market, at this stage of the lifecycle.
They want evidence-ready compliance. Audit-ready packages that assemble themselves from governed, source-traceable evidence rather than requiring consultants to manually compile evidence binders in the final weeks before a submission.
And they want lifecycle orchestration. The ability to manage the entire device lifecycle as a connected, governed system rather than a sequence of handoffs between engineering, quality, regulatory, and post-market teams — each with its own tools, its own tribal knowledge, and its own way of falling out of sync with the others.
These are not product features. They are a fundamentally different way of delivering MedTech consulting. The consultancy that can offer this doesn’t just win the current project — it becomes the strategic intelligence partner for the client’s entire device portfolio.
The Uncomfortable Truth About Traditional PLM
Traditional PLM systems — Windchill, Teamcenter, Arena — were designed for a specific job: managing documents, workflows, and change orders across the product lifecycle. They do this well. But they were architected in a pre-AI world, and their fundamental model is workflow orchestration, not intelligence orchestration.
Here’s what PLM does well. It stores design files in controlled repositories. It routes documents through review and approval workflows. It manages change orders and revision history. It tracks bill of materials and configuration. It enforces access controls and audit trails. For a regulated medical device, these are necessary capabilities — and they are not going away.
Here’s what PLM doesn’t do. It doesn’t understand the semantic content of a design history file. It doesn’t reason across regulatory frameworks to identify compliance gaps. It can’t connect a risk control to its verification evidence to its validation test result to its regulatory submission clause as a governed, queryable fabric. It doesn’t detect when a design change in subsystem A creates a new risk pathway in subsystem B. It doesn’t generate audit-ready evidence packages from source-traced, governed intelligence. And it can’t learn from the accumulated knowledge of every device program the consultancy has delivered.
The gap between “manages documents and workflows” and “understands contexts, reasons across them, and orchestrates intelligence” is the gap between PLM and device development lifecycle intelligence. It is not a small gap. It is the difference between a filing cabinet that knows where documents live and a colleague who knows what those documents mean.
This is not about replacing PLM. PLM remains the system of record. The intelligence layer sits above it — a governed semantic fabric that connects what PLM stores to what the engineering, quality, and regulatory teams actually need to know. The same logic applies to eQMS, MES, and the rest of the regulated stack. The intelligence layer makes them more valuable, not obsolete.
Device Development Lifecycle Intelligence — What It Actually Means
Device development lifecycle intelligence is a governed, agentic layer that connects design controls, risk management, verification & validation, and regulatory context into an auditable fabric across the entire device lifecycle. That definition can sound abstract until you walk through a concrete scenario.
Imagine a Class II connected diagnostic device. The engineering team changes the Bluetooth communication protocol in the embedded software. In a traditional PLM + consultancy model, this triggers a familiar sequence. A manual change order is filed. A consultant reviews the design history file to identify downstream impacts. Someone manually checks whether IEC 62304 software classification is affected. Someone manually assesses whether the cybersecurity risk analysis needs updating. Someone manually evaluates whether the 510(k) predicate comparison is still valid. Someone manually updates the verification and validation plan. Total elapsed time: two to four weeks, several consultant-hours, and a non-trivial chance that something quietly falls through the cracks because the trace matrix is held together by tribal knowledge and PDF cross-references.
In a device development lifecycle intelligence model, the same change unfolds very differently. The change is ingested by the governed intelligence fabric. The system reasons across the design control matrix, risk management file, software classification, cybersecurity risk analysis, and regulatory submission strategy — simultaneously, not sequentially. It surfaces a specific, structured response: this change affects IEC 62304 classification, triggers a cybersecurity risk review under FDA pre-market guidance, and requires updated V&V protocols for the wireless communication subsystem; the 510(k) predicate comparison is not affected. It generates a governed evidence package showing every connection, every source, every regulatory clause — auditable, traceable, human-reviewable. Total elapsed time: minutes. The consultant reviews and signs off rather than assembling from scratch.
The key distinction is what happens to the consultant’s expertise. It doesn’t disappear. It elevates. Instead of spending hours assembling evidence and tracing connections manually, the consultant spends minutes reviewing governed intelligence and exercising judgment on edge cases. The work is better, faster, and more defensible — and the consultancy can serve more clients without linearly scaling headcount. This is the same shift we described in Beyond the Glue Layer: the value moves from manual integration to governed reasoning, and the firms that own the reasoning own the relationship.
The Three Levels of MedTech Consultancy Evolution
The evolution isn’t a threat. It’s a constructive progression, and most firms can identify which level they currently operate at — and which level they’re trying to reach.
Level 1: Selling Hours. The traditional model. Deep experts doing deep work. Clients pay for time, firms deliver documentation and submissions. Margin comes from utilization. Growth comes from hiring. This is the model that built the industry, and there is nothing wrong with it — except that the ceiling on it is the number of qualified people you can recruit and retain, and that ceiling is getting lower every year.
Level 2: Selling Outcomes. The transitional model. Some firms have moved here — fixed-price engagements, milestone-based delivery, productized service packages. Better for clients, harder to execute. It requires internal process discipline and repeatability that many hours-based firms lack. It’s a meaningful step forward, but it is still fundamentally a labor model with better pricing.
Level 3: Selling Intelligence. The emerging model. The consultancy doesn’t just deliver documents or outcomes — it delivers governed intelligence. Every device program contributes to a cumulative knowledge fabric. The consultancy’s competitive advantage compounds across clients rather than resetting with each new engagement. The governed intelligence substrate becomes the differentiator. Individual consultant expertise — which competitors can always hire away — becomes one input to a larger, defensible asset.
The strategic insight for consultancy leaders is that Level 3 doesn’t replace Level 1 expertise. It monetizes it differently. The regulatory strategist who has navigated 200 FDA submissions doesn’t become less valuable. She becomes the trainer, validator, and edge-case resolver for a governed system that captures and scales her institutional knowledge. The firm stops losing her judgment every time she goes on vacation, and stops losing it permanently when she eventually retires.
Why This Moment Matters — The Window Is Open but Closing
The MedTech consultancy market is at a structural inflection point, and several forces are converging at the same time.
Federal and state AI investments are accelerating. Governments are funding AI integration in MedTech through a growing constellation of programs and initiatives. The firms that win this funding are building competitive advantages right now, not in some hypothetical future budget cycle. Late movers will read about the early ones in trade press and wonder how they got there so fast.
The FDA is signaling. The agency’s evolving guidance on AI/ML in medical devices, the April 2026 AI cGMP warning letter, and the Total Product Life Cycle approach all point in the same direction: AI is coming to regulated device development, and the regulatory framework is adapting to accommodate it. The question facing every consultancy is whether to lead this shift or follow it.
OEM demand is shifting. Large device manufacturers are consolidating their consultant panels and asking for strategic operational partners, not just project-level engineering support. The consultancies that can offer governed lifecycle intelligence will win those relationships. The ones that can only quote rates and bench depth will be relegated to overflow work, where margins compress every year.
And the advantage compounds. The firms that start building governed intelligence capabilities now will have a 2-3 year head start by the time the market normalizes. Every device program they deliver contributes to a richer knowledge fabric. Every regulatory submission teaches the system. Every risk analysis makes the next one faster. This advantage compounds — and late movers can’t shortcut it by buying a tool. They have to live through the same accumulation cycle, against competitors who started years earlier.
The frustration we hear across the market today — the same fatigue documented in AI Frustration in Life Sciences & MedTech — is not noise. It is the clearest signal that the opportunity surface is here, now, and that the firms willing to engage with the hard part will own what comes next.
The Architecture of Device Development Lifecycle Intelligence
For the technically curious reader, it’s worth describing what device development lifecycle intelligence actually looks like at an architectural level. Three principles do most of the work.
Semantic understanding, not document storage. Traditional PLM stores files. The intelligence layer understands what those files mean — design inputs, design outputs, risk controls, verification protocols, regulatory requirements — as structured, queryable, governed knowledge. This is powered by a semantic model that represents the relationships between every element of the device development lifecycle. A change to one node is not just a change to a file; it is a change with known semantic consequences, which the system can reason about.
Governed agentic reasoning. Not generic AI that hallucinates freely, but purpose-built agentic intelligence that operates within governed boundaries. Every inference is classified — fact, derived, hypothesis, or risk. Every source is traced. Every conclusion is auditable. The Interpretive Boundary Layer ensures that probabilistic AI judgment is made visible and governable before it reaches engineering or regulatory decisions. This is the difference between a tool that produces a confident-sounding paragraph and a system that produces an evidence-backed conclusion you can defend in front of an auditor.
System-of-record preserving. The intelligence layer doesn’t replace existing systems. PLM remains the system of record. eQMS remains the quality system. The intelligence fabric connects them, reasons across them, and produces governed outputs — while respecting every validation, access control, and audit trail requirement that regulated environments demand. The IT and quality organizations don’t have to choose between adopting AI and protecting the validated state of their stack. The intelligence layer is additive, not invasive.
What Forward-Thinking Firms Are Doing Right Now
The MedTech consultancies moving earliest on device development lifecycle intelligence share a recognizable pattern. They treat AI not as a tool to bolt onto existing processes but as an architectural shift in how they deliver consulting services. They invest in internal AI capability — hiring AI scientists, pursuing federal funding — while seeking partners who bring the governed intelligence substrate so they don’t have to build it from scratch. They pilot with specific device programs rather than trying to transform everything at once: a connected diagnostic, a Class III implant, a SaMD submission. They frame the shift internally as “making our experts more powerful” rather than “replacing people with AI,” because in regulated environments human judgment remains essential and culture matters as much as technology. And they are looking for strategic intelligence allies rather than vendors — partners who understand that the real value is in the governed fabric, not the feature list.
For firms thinking about how to operationalize this in practice, the Partner Acceleration Playbook describes the 30/60/90 model that turns governed AI delivery into a repeatable engine — accelerators, reusable assets, and a delivery factory that compounds across clients rather than restarting with each engagement.
The Firms That Architect the Shift Will Own It
The MedTech consultancy landscape is bifurcating. On one side: firms that see AI as a productivity tool, bolt on generic copilots, and continue selling hours. On the other: firms that recognize device development lifecycle intelligence as a structural shift in how regulated device programs are delivered — and invest in the governed intelligence architectures that make it real.
The firms that architect this shift won’t just win more projects. They will redefine what “MedTech consultancy” means. They will move from selling engineering hours to selling governed, lifecycle-spanning intelligence that compounds across every device program they deliver. Their competitive advantage won’t be individual expertise — which can always be hired away — it will be the cumulative governed knowledge fabric that no competitor can replicate.
The question for every MedTech consultancy leader reading this isn’t whether this shift is coming. It’s whether your firm will be the one that defines it.
Empower AI is building the governed intelligence substrate for regulated device development. If your firm is exploring how device development lifecycle intelligence could reshape your delivery model, we’d welcome the conversation.